Coexistence of hepatitis B surface antigen and antibody to hepatitis B surface may increase the risk of hepatocellular carcinoma in chronic hepatitis B virus infection: A retrospective cohort study

Journal of Medical Virology

Volumn 86, Issue 1, 2014, Pages 124-130

  Seo, Seung In ^a   Choi, Hyeok Soo ^a   Choi, Bo Youn ^a   Kim, Hyoung Su ^a   Kim, Hak Yang ^a   Jang, Myoung Kuk ^a  

^a Kangdong Sacred Heart Hospital   (South Korea)

Author keywords

Chronic HBV infection; Coexistence; Hepatitis B surface antigen and antibody to hepatitis B surface; Hepatocellular carcinoma

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; CANCER RISK; CHRONIC HEPATITIS; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; GENDER; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; VIRUS INFECTION;

HEPATITIS B VIRUS;

CHRONIC HBV INFECTION; COEXISTENCE; HEPATITIS B SURFACE ANTIGEN AND ANTIBODY TO HEPATITIS B SURFACE; HEPATOCELLULAR CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 84887816170     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23779     Document Type: Article

References (30)

1. Bouchard MJ, Navas-Martin S. 2011. Hepatitis B and C virus hepatocarcinogenesis: Lessons learned and future challenges. Cancer Lett 305:123-143.
2. Bruix J, Sherman M, American Association for the Study of Liver D. 2011. Management of hepatocellular carcinoma: An update. Hepatology 53:1020-1022.
3. Chen CJ, Yang HI. 2011. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 26:628-638.
4. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. 2006a. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 130:1153-1168.
5. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, REVEAL-HBV Study Group. 2006b. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73.
6. Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC, Lu SN, Changchien CS. 2007. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 133:1466-1474.
7. Chisari FV, Filippi P, Buras J, McLachlan A, Popper H, Pinkert CA, Palmiter RD, Brinster RL. 1987. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci USA 84:6909-6913.
8. Chou YC, Yu MW, Wu CF, Yang SY, Lin CL, Liu CJ, Shih WL, Chen PJ, Liaw YF, Chen CJ. 2008. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut 57:91-97.
9. Colson P, Borentain P, Motte A, Henry M, Moal V, Botta-Fridlund D, Tamalet C, Gerolami R. 2007. Clinical and virological significance of the co-existence of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers. Virology 367:30-40.
10. Hagen TM, Huang S, Curnutte J, Fowler P, Martinez V, Wehr CM, Ames BN, Chisari FV. 1994. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci USA 91:12808-12812.
11. Heijtink RA, van Hattum J, Schalm SW, Masurel N. 1982. Co-occurrence of HBsAg and anti-HBs: Two consecutive infections or a sign of advanced chronic liver disease? J Med Virol 10:83-90.
12. Hsieh YH, Su IJ, Wang HC, Chang WW, Lei HY, Lai MD, Chang WT, Huang W. 2004. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis 25:2023-2032.
13. Huang X, Qin Y, Zhang P, Tang G, Shi Q, Xu J, Qi F, Shen Q. 2010. PreS deletion mutations of hepatitis B virus in chronically infected patients with simultaneous seropositivity for hepatitis-B surface antigen and anti-HBS antibodies. J Med Virol 82:23-31.
14. Huzly D, Schenk T, Jilg W, Neumann-Haefelin D. 2008. Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen. J Clin Microbiol 46:1298-1306.
15. Jang JS, Kim HS, Kim HJ, Shin WG, Kim KH, Lee JH, Kim HY, Kim DJ, Lee MS, Park CK, Jeong BH, Kim YS, Jang MK. 2009. Association of concurrent hepatitis B surface antigen and antibody to hepatitis B surface antigen with hepatocellular carcinoma in chronic hepatitis B virus infection. J Med Virol 81:1531-1538.
16. Kao JH. 2007. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int 1:415-430.
17. Lada O, Benhamou Y, Poynard T, Thibault V. 2006. Coexistence of hepatitis B surface antigen (HBsAg) and anti-HBs antibodies in chronic hepatitis B virus carriers: Influence of "a" determinant variants. J Virol 80:2968-2975.
18. Lavanchy D. 2004. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11:97-107.
19. Lee BS, Cho YK, Jeong SH, Lee JH, Lee D, Park NH, Ki M, Korean Hepatitis Epidemiology Study G. 2013. Nationwide seroepidemiology of hepatitis B virus infection in South Korea in 2009 emphasizes the coexistence of HBsAg and anti-HBs. J Med Virol 85:1327-1333.
20. Lin CL, Kao JH. 2008. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci 15:137-145.
21. Lin CL, Liu CH, Chen W, Huang WL, Chen PJ, Lai MY, Chen DS, Kao JH. 2007. Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. J Gastroenterol Hepatol 22:1098-1103.
22. Mun HS, Lee SA, Jee Y, Kim H, Park JH, Song BC, Yoon JH, Kim YJ, Lee HS, Hyun JW, Hwang ES, Kook YH, Kim BJ. 2008. The prevalence of hepatitis B virus preS deletions occurring naturally in Korean patients infected chronically with genotype C. J Med Virol 80:1189-1194.
23. Ponde RA. 2011. The underlying mechanisms for the "simultaneous HBsAg and anti-HBs serological profile." Eur J Clin Microbiol Infect Dis 30:1325-1340.
24. Shiels MT, Taswell HF, Czaja AJ, Nelson C, Swenke P. 1987. Frequency and significance of concurrent hepatitis B surface antigen and antibody in acute and chronic hepatitis B. Gastroenterology 93:675-680.
25. Sinn DH, Choi MS, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Yoo BC. 2013. Pre-s mutation is a significant risk factor for hepatocellular carcinoma development: A long-term retrospective cohort study. Dig Dis Sci 58:751-758.
26. Song BC, Cui XJ, Kim H. 2005. Hepatitis B virus genotypes in Korea: An endemic area of hepatitis B virus infection. Intervirology 48:133-137.
27. Trepo CG, Robert D, Motin J, Trepo D, Sepetjian M, Prince AM. 1976. Hepatitis B antigen (HBSAg) and/or antibodies (anti-HBS and anti-HBC) in fulminant hepatitis: Pathogenic and prognostic significance. Gut 17:10-13.
28. Wang YM, Ng WC, Lo SK. 1999. Detection of pre-S/S gene mutants in chronic hepatitis B carriers with concurrent hepatitis B surface antibody and hepatitis B surface antigen. J Gastroenterol 34:600-606.
29. Wang HC, Huang W, Lai MD, Su IJ. 2006. Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci 97:683-688.
30. Weinberger KM, Zoulek G, Bauer T, Bohm S, Jilg W. 1999. A novel deletion mutant of hepatitis B virus surface antigen. J Med Virol 58:105-110.